The combination of cagrilintide (an amylin analog) with semaglutide (CagriSema) produced 9% greater weight loss than semaglutide alone, while cagrilintide by itself matched semaglutide's effectiveness with fewer vomiting side effects.
-9.11 kg more than semaglutideCagriSema (cagrilintide + semaglutide combination) produced dramatically more weight loss than semaglutide alone over 20-32 weeks
What the researchers found
Key results from 3 RCTs with 430 participants:
**CagriSema vs semaglutide 2.4 mg (20-32 weeks):**
- Extra percentage weight loss: -9.07% (95% CI: -11.91 to -6.23)
- Extra absolute weight loss: -9.11 kg (95% CI: -12.84 to -5.39)
- GI adverse events and vomiting were significantly higher with CagriSema
**Cagrilintide 2.4 mg vs semaglutide/liraglutide (26-32 weeks):**
- Percentage weight loss: similar (MD -1.83%, non-significant, p=0.11)
- Absolute weight loss: similar (MD -1.88 kg, non-significant, p=0.12)
- Vomiting was significantly lower with cagrilintide
Treatment-emergent and serious adverse events were comparable across all groups.
Why it matters
CagriSema represents the next frontier in peptide-based obesity treatment — combining two different appetite-suppressing peptide pathways (GLP-1 and amylin) in a single weekly injection. The finding that it outperforms semaglutide alone by a substantial 9 kg is remarkable, as semaglutide was already considered the gold standard. This combination could set new benchmarks for non-surgical weight loss.
How the study worked
Systematic review and meta-analysis searching electronic databases for randomized controlled trials of cagrilintide alone or CagriSema in obese individuals compared to placebo or active comparators. Three RCTs with 430 participants were included. Primary outcomes were body weight changes; secondary outcomes included glycemia, lipids, and adverse events.
What this study cannot tell us
Only 3 RCTs with 430 participants were available for analysis — a small evidence base for a meta-analysis. High heterogeneity (I² = 96-98%) across studies suggests inconsistency in effect sizes, limiting confidence in the pooled estimates. Study durations were relatively short (20-32 weeks), and long-term efficacy and safety remain unknown. The increased GI side effects with CagriSema may limit tolerability for some patients.
How to read the evidence
This is a meta-analysis of 3 randomized controlled trials, providing moderate-quality evidence. The small number of trials, limited sample size (430 participants), and high heterogeneity are significant limitations. Phase 3 trials with larger cohorts will be needed to establish definitive efficacy and safety profiles.
When this study was published
Published in 2024, this meta-analysis captures early clinical trial data for CagriSema. Larger Phase 3 trials are underway and will provide more definitive evidence. This remains among the most current analyses of this emerging combination therapy.
The bigger picture
The obesity treatment landscape is evolving rapidly from single-target peptide drugs to multi-peptide combinations. CagriSema (cagrilintide + semaglutide) represents a new approach: combining GLP-1 signaling with amylin signaling for additive appetite suppression. If Phase 3 trials confirm these results, CagriSema could become the most effective non-surgical weight loss treatment available, potentially achieving weight reductions previously only seen with bariatric surgery.
Questions still open
- Will CagriSema's superiority over semaglutide persist in larger Phase 3 trials with longer follow-up?
- Can the GI side effects of CagriSema be managed with slower dose titration without sacrificing efficacy?
- How does CagriSema compare to tirzepatide (the dual GLP-1/GIP agonist) for weight loss in head-to-head comparisons?
Common questions
What is cagrilintide and how does it differ from semaglutide?
When will CagriSema be available?
Read the original research
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
Indian journal of endocrinology and metabolism, 28(5), 436-444
Citation
Dutta, Deep; Nagendra, Lakshmi; Harish, B G; Sharma, Meha; Joshi, Ameya; Hathur, Basavanagowdappa; Kamrul-Hasan, Abm. (2024). Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.. Indian journal of endocrinology and metabolism, 28(5), 436-444. https://doi.org/10.4103/ijem.ijem_45_24